13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Clover Ascites

    Acronym: 

    TRAIL Trimer

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Other
    Trial Type Treatment
    Phase Phase I Tumour Stream Malignant Ascites
    Age Range 18 years and older Cancer Stage Clinical Trials - Cancer Stage
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Other
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Malignant Ascites
    Cancer Stage Clinical Trials - Cancer Stage
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A Phase 1 study evaluating the safety, tolerability, efficacy and pharmacokinetics of the SCB-313, a fully-human TRAIL-trimer fusion protein, for the treatment of malignant ascites

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Ganessan Kichenadasse Recruiting